Apellis Pharmaceuticals Inc (APLS)
49.93
+1.21
(+2.48%)
USD |
NASDAQ |
Apr 24, 16:00
49.86
-0.07
(-0.14%)
After-Hours: 20:00
Apellis Pharmaceuticals Revenue (TTM): 396.59M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 396.59M |
| September 30, 2023 | 272.88M |
| June 30, 2023 | 184.53M |
| March 31, 2023 | 105.89M |
| Date | Value |
|---|---|
| December 31, 2022 | 75.42M |
| September 30, 2022 | 113.05M |
| June 30, 2022 | 96.64M |
| March 31, 2022 | 80.94M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
75.42M
Minimum
Dec 2022
396.59M
Maximum
Dec 2023
165.74M
Average
109.47M
Median
Revenue (TTM) Benchmarks
| Sarepta Therapeutics Inc | 1.243B |
| Blueprint Medicines Corp | 249.38M |
| Alnylam Pharmaceuticals Inc | 1.828B |
| Ionis Pharmaceuticals Inc | 787.65M |
| Madrigal Pharmaceuticals Inc | -- |